High-dose VP16 cisplatinum in soft tissue sarcoma of children.
Nine children with soft tissue sarcomas, five of them rhabdomyosarcomas with initial metastatic disease, (one patient, partial response, one patient), refractory primary, (two patients, relapse, five patients) were treated with a combination of high-dose VP16 (100 mg/m2 daily for 5 days) and cisplatin (40 mg/m2 daily for 5 days). The response rate was five out of nine or 55% (+/- 32%) (two complete and three partial, responses). Three of the five responders had rhabdomyosarcomas. The duration of response was 4-58 months (median 11 months). The toxicity was mainly hematological. Thus, the high-dose VP16-cisplatin association warrants further evaluation in soft tissue sarcoma in children.
Grabois
M
M
Pediatric Department of Centre Leon Berard, Lyon, France.
Frappaz
D
D
Bouffet
E
E
Carrie
C
C
Bouhour
D
D
Philip
T
T
Brunat-Mentigny
M
M
D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D002945:Cisplatin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008297:Male; D012509:Sarcoma / Q000188:drug therapy*; D016896:Treatment Outcome
D005047:Etoposide; D002945:Cisplatin